Skip to content

BioNTech

US · BNTX #801 by market cap Listed 2019
80.96 -0.42 -0.52%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About BioNTech

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Founded
2008
CEO
Professor Ugur Sahin, M.D.
Employees
7,807
Headquarters
Mainz, Rheinland-Pfalz, Germany
Fiscal year end
12-31
Website
biontech.de

Company profile

Exchange
US
Symbol
BNTX
Market-cap rank
#801
Listing date
2019-10-10
Market cap
20.07B
Float cap
8.58B
Shares out
247.93M
Float shares
106.00M

Sectors & themes

Biotechnology Infectious Disease Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

BioNTech discussion 0 comments

Add a comment